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Abstract
The Henry Ford Hospital (HFH) regadenoson (REG) registry includes patients with a variety of comorbidities allowing for
the evaluation of outcomes in a large, unselected population. Using a database of electronic medical records and nuclear
cardiology reports, patients aged > 18 years who underwent REG-facilitated single-photon emission computed tomography
(SPECT) testing at HFH between January 2009 and August 2012 were identified. The primary objective was to describe the
clinical and demographic characteristics of patients who had undergone REG only vs REG WALK (REG + low-level exercise)
SPECT. A total of 2104 patients were included in the analysis (mean age 65.3 years; 50% women; 51% African American,
43% Caucasian). For the REG only (n = 1318) and REG WALK (n = 786) cohorts, SPECT was abnormal in 37% of patients
(REG only, 39%; REG WALK, 34%; P < 0.01). No differences in diagnostic modalities or interventions in 90 days after
SPECT were observed. Immediate safety analysis showed no deaths 48 h after REG SPECT testing. Although they guide
invasive therapy, abnormal scans do not automatically lead to invasive testing. This demonstrates the focus on initial medical
management, which reflects the existing evidence of initial goal-directed medical management of stable coronary disease.
Keywords Regadenoson · Single-photon emission computed tomography · Pharmacological stress agent · Coronary artery
disease · Stress testing outcomes

Introduction
Cardiovascular disease (CVD) is the leading cause of death
in the United States (US), and disproportionate rates persist
in racial and ethnic minority populations [1]. Single-photon
emission computed tomography myocardial perfusion imaging (SPECT-MPI) with cardiac stress induced by exercise
or a pharmacological stress agent (PSA) is an extensively
validated method for the diagnosis and prognostic assessment of coronary artery disease (CAD) [2, 3]. Patients able
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to walk on a treadmill are often referred for exercise SPECTMPI; however, ambulatory patients unable to achieve at least
85% of the maximum predicted heart rate and five metabolic
equivalents with exercise alone are often referred for pharmacologic stress testing combined with low-level exercise
[4–6]. Relative to PSA alone, this approach is well tolerated
and improves image quality.
Regadenoson (REG) is the most commonly used PSA
with SPECT-MPI largely because of its A2a selectivity,
ease of preparation, standardized dosing, proven efficacy,
and comparability to adenosine myocardial perfusion imaging [7–10]. REG has demonstrated safety and tolerability in
both clinical trials and in real-world studies. Indeed, clinical
trial results show REG is well tolerated irrespective of age,
gender, or presence of comorbidities (eg, diabetes, chronic
obstructive pulmonary disease, asthma, chronic kidney disease) [11–16]. In an unpublished, previously conducted,
single-center, retrospective analysis of patients undergoing REG SPECT, we compared hemodynamic and stress
variables and immediate safety outcomes between REG
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SPECT and REG WALK SPECT (ie, REG combined with
low-level exercise). In this study, no major adverse events
(AEs) occurring immediately after testing were reported,
and aminophylline use was more commonly reported with
REG SPECT compared to REG WALK SPECT (11.4% vs
5.6%; P = 0.001).
Less is known, however, about the immediate and downstream effects of REG SPECT in real-world practice, including the effects on treatment decisions, and how certain baseline patient clinical and demographic characteristics impact
these effects. Although revascularization has shown survival
benefits for patients with moderate to severe ischemia per
SPECT [17], several studies conducted over the past decade have demonstrated that patients with stable coronary
disease can be effectively managed with optimized medical
management [18, 19]. Describing the daily clinical use of
REG SPECT in a larger unselected patient population with
regard to patient characteristics and the downstream effects
on patient management (eg, revascularization vs medical
management) may provide valuable insight to clinicians
considering REG SPECT for their patients. Consequently,
the purpose of this study was to gain a better understanding
of the immediate and downstream outcomes of REG SPECT
stress testing with and without low-level exercise according
to baseline patient characteristics among an unselected realworld population of varying ages and races/ethnicities and
with various comorbidities and/or receiving concomitant
medications.

Materials and methods
Study design
This was a retrospective, secondary analysis of data obtained
from the Henry Ford Hospital (HFH) REG SPECT registry,
a registry containing patient demographics, characteristics,
stress test and SPECT variables, and outcomes obtained
from unselected patients who underwent REG SPECT.
Patient records, nuclear cardiology reports, and information
from electronic medical records were manually extracted
to further populate the database for this study, containing
deidentified patient-level data on clinical and demographic
characteristics and patient outcomes. Per our lab protocol,
standardized semiquantitative SPECT perfusion interpretation was used; study results were classified as normal
(summed stress score [SSS] = 0), probably normal (SSS
1–3 and summed difference score [SDS] < 2), and abnormal (SSS ≥ 4 and SDS ≥ 2). Furthermore, SSS was categorized as mildly (4–7), moderately (8–12), and severely
(≥ 13) abnormal; and SDS as mild (2–4), moderate (5–7),
and severe (> 7) ischemia. Abnormal study results also considered were low ejection fraction (< 50%) and ischemic
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electrocardiographic responses with pharmacologic stress.
All program software scoring was reviewed by the SPECT
reader and adjusted, as needed. All studies were read by certified nuclear cardiologists or nuclear medicine physicians
integrating clinical and SPECT data into a final impression.
All semiquantitative scoring by the program was reviewed
and adjusted routinely by the readers prior to final reporting.
The primary objective of this study was to describe the
clinical and demographic characteristics of the patient population who have undergone SPECT-MPI using adjunct lowlevel exercise (REG WALK) or REG alone (REG only) or
who have converted from an inadequate exercise test (REG
CONVERT). The secondary objectives included (1) assessing healthcare resource utilization and clinical outcomes
in the overall population and within racial and ethnic subgroups (African American, Caucasian, Hispanic, and nonHispanic patients), and (2) to determine patient characteristics associated with downstream outcomes (eg, cardiac and
non-cardiac death, myocardial infarction [MI], heart failure)
in the overall REG-SPECT population and in specific subgroups (ie, patients with asthma, chronic obstructive pulmonary disease, end-stage renal disease on dialysis, obesity,
severe left ventricular dysfunction, left bundle branch block/
paced rhythm, history of stroke and seizures) over a 90-day
period following SPECT. Exploratory outcomes included
describing immediate clinical events and use of aminophylline for AEs in the overall population and within racial and
ethnic subgroups (African American, Caucasian, Hispanic,
and non-Hispanic patients). Medical management decisions
were evaluated as addition of cardiac specific medications in
the time period of 90 days post SPECT (antiplatelets, beta
blockers, calcium channel blockers, nitrates and statins).

Selection of the study population
Patients aged ≥ 18 years who underwent REG-facilitated
SPECT testing at HFH (January 2009–August 2012) were
identified. Exclusion criteria were limited to research protocol participation (in HFH research trials of SPECT) and
pregnancy. At HFH, trained stress lab nurses or cardiac
diagnostic technicians assess all patients regarding their
ability to perform adjunctive low-level exercise as part of
REG SPECT by asking directed questions regarding ability
to perform daily activities. If it is determined that the patient
is unable to exercise based on physical limitations or refusal,
they are offered REG SPECT alone. Other exclusions for
REG WALK included those with left bundle branch blocked
or paced rhythm. Those deemed appropriate for REG WALK
and able to exercise then perform adjunctive low-level exercise for 1.5 min on Stage 1 of the modified Bruce protocol
followed by REG and saline flush with continued exercise
for another 2 min (Fig. 1).
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Fig. 1  REG WALK Protocol. mcg microgram, REG regadenoson

Analysis
A total of 2104 patients undergoing REG-facilitated SPECT
in the specified time period were included in this analysis.
Categorical variables were compared between groups using
chi-square tests, while continuous variables were compared
using independent 2-group t-tests. In the case of pairwise
comparisons, a Benjamini–Hochberg correction was applied,
and the adjusted P-value was reported. Analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA),
with statistical significance set at P < 0.05.

Results
Patient characteristics
A total of 2126 patients met the eligibility criteria. For the
analyses, 22 patients (1%) undergoing REG CONVERT
were excluded, owing to the low patient numbers, and are
not discussed further herein. Patient characteristics at the
time of index SPECT testing and proportion of patients
with a normal, mildly abnormal, and moderate to severe
SSS and normal, mildly abnormal, moderately abnormal,
and severely abnormal SDS are summarized in Table 1.
The primary indications of SPECT included evaluating
patients presenting with chest pain or equivalent symptoms for CAD, screening for preoperative evaluations,
screening for CAD in high-risk asymptomatic patients,
and screening for other miscellaneous causes. Overall, for
the 2104 patients included in the analysis, mean age was
65.3 years, with women and African Americans comprising 50% and 51% of the sample, respectively (43% were
Caucasian). Significant differences between the REG only
(n = 1318) and REG WALK (n = 786) cohorts with respect
to age, sex, ethnic group, and points of origin, but not race,
were observed. The REG only cohort had a significantly
higher rate of diabetes and most other cardiopulmonary

comorbidities, and the majority of all patients (60–67%)
were receiving at least 3 of the most commonly used cardiac medications, namely aspirin, statins, or beta blockers. Comorbidities according to race are summarized in
Table 2. For the REG only (n = 1318) and REG WALK
(n = 786) cohorts, SPECT was abnormal in 37% of patients
(REG only, 39%; REG WALK, 34%; P < 0.01). The overall
burden of severe ischemia (defined as SDS > 7) was low, at
4.8% in the entire study population. Eighty-seven percent
of the entire study group had no to mild ischemia (SDS
0–4), with only 19% of patients having clinically significant ischemia (SDS ≥ 2; n = 394).

Safety
Overall, 43% of patients undergoing REG SPECT had
arrhythmias, with similar rates occurring in the REG only
and REG WALK cohorts (45.1% [595/1318] and 40.6%
[319/786] respectively; P = 0.123). Premature atrial contraction/atrial premature beats were reported in 8% of patients
overall and 9% and 6% of patients undergoing REG only and
REG WALK, respectively; premature ventricular contraction
was reported in 25% of patients overall and 26% and 24% of
patients after REG only and REG WALK, respectively. No
significant bradyarrhythmias, tachyarrhythmias, atrial flutter, atrial fibrillation, or ventricular tachycardia requiring
immediate intervention were documented.
The need for aminophylline and other immediate clinical events is summarized in Fig. 2. The significantly higher
rates of aminophylline use and flushing in the REG only
cohort could be secondary to lack of supplemental exercise,
which is known to minimize side effects, and higher comorbidity rates relative to the REG WALK cohort. The use of
adjunctive low-level exercise was associated with a lower
incidence of flushing (Fig. 2). Immediate safety analysis
showed no deaths within 48 h for both REG only and REG
WALK SPECT.
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Table 1  Patient demographics
and clinical characteristics at
index SPECT test and reported
SPECT results categorized by
SSS and SDS

Baseline characteristics, n (%)

All patients
(n = 2104)

REG only
(n = 1318)

REG WALK
(n = 786)

P-value
(REG only vs
REG WALK)

Age, mean ± standard deviation

65.3 ± 12.5

67.7 ± 12.3

61.2 ± 11.9

< 0.001

Male

1055 (50%)

591 (45%)

464 (59%)

< 0.001
< 0.001

Female

1049 (50%)

727 (55%)

322 (41%)

Caucasian

846 (43%)

532 (43%)

314 (43%)

0.989

African American

988 (51%)

618 (50%)

370 (51%)

0.989

Other

121 (6%)

76 (6%)

45 (6%)

0.989

Hispanic/Latino

53 (3%)

24 (2%)

29 (4%)

< 0.001

Not Hispanic/Latino

1711 (92%)

1051 (92%)

660 (93%)

< 0.001

Other

89 (5%)

70 (6%)

19 (3%)

< 0.001

Point of service

1 (0%)

0 (0%)

1 (0%)

0.195

PPO

33 (2%)

16 (1%)

17 (2%)

0.090

HMO

77 (4%)

42 (3%)

35 (4%)

0.135

Commercial

282 (13%)

163 (12%)

119 (15%)

0.071

Medicare/Medicaid

1150 (55%)

821 (62%)

329 (42%)

< 0.001

Unknown/missing

616 (29%)

314 (24%)

302 (38%)

< 0.001

Outpatient

1440 (68%)

821 (62%)

619 (79%)

< 0.001

Inpatient

663 (32%)

497 (38%)

166 (21%)

< 0.001

Diabetes

918 (44%)

604 (46%)

314 (40%)

Chronic obstructive pulmonary disease

225 (11%)

185 (14%)

40 (5%)

Asthma

273 (13%)

182 (14%)

91 (12%)

Cerebrovascular accident

264 (13%)

201 (15%)

63 (8%)

0.009
< 0.001
0.144
< 0.001

Smoking

1118 (54%)

716 (55%)

402 (52%)

0.117

Hypercholesterolemia

1497 (71%)

946 (72%)

551 (70%)

0.412

Coronary artery disease

728 (35%)

494 (37%)

234 (30%)

< 0.001

Hypertension

1848 (88%)

1186 (90%)

662 (84%)

< 0.001

Myocardial infarction

569 (27%)

379 (29%)

190 (24%)

0.020

Ejection fraction < 50%

180 (20%)

134 (22%)

46 (15%)

0.009

Seizure

38 (2%)

25 (2%)

13 (2%)

0.682

End-stage renal disease

113 (11%)

55 (9%)

58 (14%)

0.020

Medications (yes)

Antihypertensive

–

907 (69%)

502 (64%)

0.017

Antiplatelet

–

191 (15%)

90 (11%)

0.047

Aspirin

–

844 (64%)

472 (60%)

0.068

Beta blocker

–

861 (65%)

527 (67%)

0.433

Calcium channel blocker

–

428 (32%)

262 (33%)

0.655

Glucose lowering

–

511 (39%)

263 (33%)

0.014

Nitrate

–

312 (24%)

153 (20%)

0.026

Statin

–

875 (66%)

497 (63%)

0.139

Summed stress scores
Normal (0–3)

–

1521 (75.6%)

–

–

Mildly abnormal (4–7)

–

210 (10.4%)

–

–

Moderate-severe (8–13)

–

282 (14.0)

–

–

Missing

–

91

–

–

Normal (< 2)

–

1624 (80.5%)

–

–

Mildly abnormal (2–4)

–

196 (9.7%)

–

–

Moderately abnormal (5–7)

–

102 (5.1%)

–

–

Severely abnormal (> 7)

–

96 (4.8%)

–

–

Missing

–

86

–

–

Summed difference score

HMO health maintenance organization, PPS preferred provider organization, REG regadenoson, SDS
summed difference score, SPECT single-photon emission computed tomography, SSS summed stress score
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Downstream effects
A significantly higher rate of medical management change
was noted with REG only vs REG WALK (P < 0.001), but
no differences in cardiac catheterizations or interventions in
the 90 days after SPECT were observed between the REG
only and REG WALK groups (Fig. 3, Fig. 2).
When stratified by SSS (0–3, 4–7, 8–13), we observed
progressively higher rates of catheterization with worsening
summed scores in both REG only and REG WALK groups
(P < 0.001 between all stratums of SSS in both groups;
Fig. 4A).
Also, with increasing ischemia burden (SDS ≥ 2),
there were progressive increases in catheterization and
Table 2  Comorbidities stratified
by race

percutaneous coronary intervention (PCI) rates in all
patients (P ≤ 0.001 for pairwise comparisons; Table 3) as
well as in the REG only and REG WALK groups (P < 0.001
for all groups; Fig. 4B and C).
With regard to medical management decisions, REG
SPECT significantly affected downstream management with
worsening SSS and SDS. As shown in Fig. 5, there were
progressive increases in medical management changes as
the severity of abnormal scans increased in both the REG
and REG WALK groups.

Variable
Comorbidities

Fig. 2  Immediate clinical
events. REG regadenoson

Diabetes
Chronic obstructive pulmonary disease
Asthma
Cerebrovascular accident
Smoking
Hypercholesterolemia
Coronary artery disease
Hypertension
Myocardial infarction
Ejection fraction < 50%
Seizure
End-stage renal disease

Caucasians
(n = 854)

African Americans
(n = 997)

P-value

347 (41%)
111 (13%)

454 (46%)
99 (10%)

0.032
0.039

102 (12%)
85 (10%)
432 (51%)
627 (73%)
328 (38%)
713 (83%)
226 (27%)
70 (18%)
11 (1%)
25 (5%)

145 (15%)
156 (16%)
573 (58%)
676 (68%)
302 (30%)
914 (92%)
277 (28%)
86 (21%)
24 (2%)
72 (16%)

0.099
< 0.001
0.003
0.008
< 0.001
< 0.001
0.519
0.328
0.080
< 0.001

100

Percentage (%) of Paents

90

REG only (n=1318)

80

REG WALK (n=786)

70
60
50
40
30
20
10
0

P<.001

20%
12%

Aminophylline use

P=0.109

22%

19%

Headache

P<.001

P=0.181

P=0.007

0% 0%

2% 3%

Muscle pain

Dizziness

21%
12%

Flushing
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Discussion
The HFH REG registry is a large database containing data
from an unselected real-world population who underwent
REG SPECT. Our sample of > 2000 patients represent a
broad, diverse, and unselected population that serves to
both characterize the various combinations of demographic
and clinical factors in patients undergoing REG SPECT and
enable the evaluation of post-test experience and outcomes
in a wide variety of patient subpopulations. Women, African
Americans, and patients with a wide range of comorbidities
were represented.
Overall, the important conclusions from our study were
that (1) use of REG SPECT in a diverse population with
multiple comorbidities is safe, with no serious immediate
AEs and excellent survival; (2) the majority of the study
population had minimal side effects, with REG WALK
patients experiencing fewer side effects and less frequent
use of aminophylline, supporting the addition of low-level
adjunctive exercise when feasible; (3) REG SPECT results
and the severity of abnormal scans and extent of ischemia
appear to influence downstream decision making, including
referral to catheterization and revascularization and medical
management changes, although many patients with abnormal scans appear to also be managed medically.
Based on conclusions from post-hoc clinical trial analyses, it was anticipated that during real-world use, REG
SPECT would be safely used regardless of patient age, gender, comorbidity, or concomitant medications. Using data
from over 2000 participants in 2 randomized phase 3 clinical trials (ADVANCE MPI 1 and 2), REG was found to be

Fig. 3  Downstream effects
(within 90 days of SPECT).
CTAcomputed tomography
angiogram, REG regadenoson

100%
90%
REG only (n=1318)

Percentage (%) of Pa ents

80%
70%

REG WALK (n=786)

60%
50%

P=0.106

P<.001

40%
30%
20%
10%
0%
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safe and effective irrespective of patient age, gender, BMI,
and the presence of comorbid diabetes, with improved tolerability over adenosine in all subgroups [20]. Clinical trials evaluating REG specifically in patients with comorbid
asthma, chronic obstructive pulmonary disease, or chronic
kidney disease collectively support its safety with no negative impact on pulmonary function [13, 14, 16, 21]. Other
retrospective findings support safety and tolerability in the
setting of pulmonary hypertension and cardiac transplantation [22, 23]. Limited real-world data are available on the
impact of some characteristics, including sex, race, and ethnicity, on the outcomes of patients undergoing REG SPECT.
One study sought to assess the impact of race and ethnicity
on the efficacy and safety of REG using clinical trial data
but was limited by the small sample sizes of several subgroups, including African Americans [12]. Regarding our
study sample, half of the patients were female, and half were
African Americans, thus providing a large subset to glean
information from with regard to REG SPECT use in these
patient subsets. Regarding the impact of race, we found that
while baseline characteristics comorbidities were higher in
African Americans vs Caucasians, abnormal SPECT findings were lower. While cardiac catheterization rates were
similar between races, PCI rates were lower and medical
management changes were higher in African Americans
(Table 4).
Overall, the types and incidences of immediate clinical
events and AEs were consistent with those expected based
on randomized clinical trial experiences. The most common
AEs reported here were headache and flushing, at 21% and
17%, respectively; corresponding incidences for REG in the
combined analysis of the ADVANCE MPI 1 and 2 trials

22%

25%

P=0.668

8% 9%

22%
14%

P=0.578

P=0.797

0% 1%

1% 1%

Catheriza on Percutaneous
Medical
Cardiac CTA
Stress test
coronary
management within 90 days within 90 days
interven on
change
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Fig. 4  Catheterization rates (within 90 days of SPECT) based on
summed stress score (SSS; A) and summed difference score (SDS;
B) and percutaneous coronary intervention rates (within 90 days of
SPECT) based on SDS (C) in the REG and REG WALK groups. PCI
percutaneous coronary intervention, REG regadenoson, SDS summed
difference score, SSS summed stress score

were 26% and 22%, respectively [20]. Randomized trials
with strict criteria for aminophylline use show lower rates of
use [24]. The use of aminophylline was substantially higher
in our registry, reflecting real-world differences. Many reasons may account for this finding. The data presented here
were from the early years of REG use and hence our clinical
team were more cautious and used aminophylline readily.
With continued experience with REG, we have noticed a
steady decline in aminophylline use, particularly over the
subsequent years (2014–2017), to about 7% (unpublished
data).
The results of this study also indicate that decisions on
use of REG only or REG WALK are driven primarily by
patient comorbidities and baseline characteristics, apart from
patient limitations and preferences. Compared with the REG
WALK cohort, the REG only cohort was older and was composed of a lower proportion of men and higher proportions
of Medicare/Medicaid recipients and patients initiating care
in an inpatient setting; additionally, those selected for REG
only had higher comorbidity rates (Table 1). This reflects
the known association of higher PSA use in this group who
are unable or unwilling to perform even low-level exercise.
Additionally, we found that increasing volume of abnormal
scans resulted in progressively higher rates of catheterization and PCI; however, not all patients with abnormal scans
underwent invasive workup. This may reflect increasing
physician comfort level with initial medical management,
which is the current trend for management of stable coronary disease. Since the publication of the COURAGE trial
in 2007, there has been an increased focus on optimal medical therapy and an improved comfort level of physicians to
use medical treatment as first-line therapy in stable CAD,
reserving invasive procedures for those with abnormal tests
and symptoms despite pharmacologic treatment [18, 25].
Typically, the decision to proceed with invasive workup
depends on various factors, such as patient risk, presence
or absence of symptoms, and preferences of the patient
and/or referring physician. The relatively low frequency
of referral of patients with abnormal SPECT to cardiac
catheterization has been previously reported in the SPARC
multicenter registry study evaluating multiple noninvasive
diagnostic modalities, including SPECT positron emission
tomography and computed tomography angiogram [26–31].
Even in patients with moderate to severe SPECT abnormalities, < 50% of patients in the SPARC registry were referred
to cardiac catheterization. Additionally, use of medications
following an abnormal scan even in these high-risk groups
in SPARC were suboptimal, with 20% to 25% of patients not
taking aspirin and statins and > 40% of patients not taking
a beta blocker. Similar results were observed in our study,
with < 50% of patients receiving a change in medication
after abnormal SPECT (Table 4). Furthermore, our study
showed that although medication changes occurred more
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Table 3  Cardiac catheterization and percutaneous coronary interventions stratified by SPECT results
SDS

Catheterization (N = 464)

Percutaneous coronary
intervention (N = 170)

Normala
Mildly abnormalb
Moderately abnormalc
Severely abnormald

273 (16.8%)
73 (37.2%)
56 (54.9%)
62 (64.6%)

92 (5.7%)
26 (13.3%)
21 (20.6%)
31 (32.3%)

Pairwise comparison

Adjusted P-value

Adjusted P-value

Normal vs mildly abnormal
Normal vs moderately abnormal
Normal vs severely abnormal
Mildly abnormal vs moderately abnormal
Mildly abnormal vs severely abnormal
Moderately abnormal vs severely abnormal

< 0.001
< 0.001
< 0.001
0.007
< 0.001
0.165

< 0.001
< 0.001
< 0.001
0.100
< 0.001
0.100

SDS summed difference score, SPECT single-photon emission computed tomography
a

b
c
d

Score: 0–3
Score: 4–7
Score: 5–7
Score: > 7

Fig. 5  Medical management changes (within 90 days of SPECT) by burden of ischemia in the REG and REG WALK groups. REG regadenoson,
SDS summed difference score
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Table 4  Downstream effects
stratified by race

Variable
Downstream effects

Catheterization
Percutaneous coronary intervention
Medical management change
Cardiac CTA within 90 days
Stress test within 90 days

Caucasians
(n = 854)

African Americans
(n = 997)

203 (24%)
87 (10%)
134 (16%)
2 (0%)
9 (1%)

215 (22%)
62 (6%)
222 (22%)
7 (1%)
12 (1%)

P-value
0.258
0.002
< .001
0.149
0.762

CTAcomputed tomography angiogram

frequently as the burden of ischemia increased, this practice
was not consistently observed in all patients with ischemia.
Another notable finding in our registry is the large number of patients with normal or near-normal SPECT scans.
As has been shown in recent studies, the declining burden of SPECT-detected ischemia is a national trend [25,
32]. There are several potential reasons for this finding,
including the testing of lower-risk populations or declining ischemia detection due to aggressive use of primary
and secondary prevention strategies for reducing cardiovascular risk, as shown by high baseline use of cardioprotective medications in our registry [26]. Likewise, there
was a progressive increase in catheterization referrals and
revascularization with worsening SSS or SDS, yet not all
patients with moderate to severe ischemia were referred
for catheterization (24% in REG and 25% in REG WALK),
similar to prior studies [25–27]. However, a combined
54% of patients with normal and mildly abnormal scans
underwent invasive workup, with 19% of this combined
group undergoing PCI (Table 3). Although this represents
a substantial number of catheterization procedures in
low risk SPECT, these data represent real world practice
predating contemporary studies such as ISCHEMIA [33]
which showed that initial medical management in stable
CAD works as well as invasive workup. Currently, with
the advances in cardiac CT and its diagnostic accuracy,
many such low risk scans get clarified with CTA rather
than catheterization and may not require further diagnostic
workup. Thus, our data represent a timeline where catheterization was primarily used rather than CT accounting
for this observation.
Although our study was not designed to identify the
exact reasons for referral and non-referral for invasive testing, based on findings in the COURAGE trial, the growing confidence in medical management of these patients, as
previously discussed, may be a generalizable finding. These
findings have recently been reinforced by the outcomes of
the ISCHEMIA trial. The ISCHEMIA study demonstrated
that initial medical therapy was equivalent to invasive and
interventional evaluation in patients without significant left
main disease and moderate to severe ischemia [33].

Our retrospective registry has several limitations. These
include those inherent to non-interventional studies using
only secondary data collection conducted outside of a prospective clinical trial, for which variability in the quality
of the clinical assessments and event reporting is expected.
Furthermore, management decisions (medical and invasive
referrals) cannot be accounted for, and missing or inaccurate data are inherent to any retrospective database. At the
same time, however, we believe that providing a real-world
unselected population undergoing pharmacologic SPECT
and its influence on management helps to reflect how clinicians are utilizing available evidence in clinical practice. We
acknowledge that the timeline of our study predates contemporary data from studies like ISCHEMIA, but it is important
to note that the ISHCHEMIA trial was started many years
ago (2012) and took over 8 years to complete, reflecting
practice evolution over many years in a rigorous randomized
approach, which may not always reflect real life practice.
REG SPECT is overall well tolerated and shows excellent short-term safety in real-world patient populations,
regardless of gender, in patients with numerous comorbidities (including those with respiratory diseases), with
no immediate safety concerns or major arrhythmic side
effects. Routine use of low-level exercise along with REG
SPECT allows for reductions in side effects and in the
need for aminophylline. The incidence of ischemia detection in patients tested for suspected CAD is declining in
the current era of aggressive medical management. However, REG SPECT guides downstream decision making
with respect to catheterization and PCI as well as medical management changes based on test abnormality, suggesting that SPECT still serves as an effective gatekeeper
in patient care. Higher use of cardiac medications with
continued medical management and referral for invasive
workup only for patients with very abnormal SPECT
results reflects the current real-world practice management
trends for stable CAD.
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